Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) shot up 7.1% during trading on Tuesday . The company traded as high as $2.33 and last traded at $2.33. 39,020 shares were traded during trading, a decline of 31% from the average session volume of 56,649 shares. The stock had previously closed at $2.18.
Medexus Pharmaceuticals Stock Performance
The firm has a 50 day moving average price of $2.47 and a two-hundred day moving average price of $2.03.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
- Five stocks we like better than Medexus Pharmaceuticals
- How to Find Undervalued Stocks
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Short Selling: How to Short a Stock
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
